Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.

ABSTRACT:

Background

Real-world comparative benefits and risks of infliximab (IFX) and adalimumab (ADA) in patients with ulcerative colitis (UC) are unclear.

Aim

To evaluate the comparative effectiveness and safety of IFX and ADA in patients with UC who were new users of anti-TNF agents.

Methods

Using an administrative claims database (Optum Labs Data Warehouse), we identified patients who received first anti-TNF (IFX, ADA) prescription after a 12-month period without any anti-TNF treatment (baseline), and with a minimum 6-month follow-up after anti-TNF initiation. Primary outcome measures were: all-cause and UC-related hospitalisation, abdominal surgery, corticosteroid use >60 days after starting anti-TNF, and serious infections. We performed 2:1 propensity-score matched Cox p

SUBMITTER: Singh S 

PROVIDER: S-EPMC4917292 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature